RecruitingPhase 2NCT05828069
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
Studying Langerhans cell histiocytosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Carl E AllenChildren's Oncology Group
- Intervention
- Biospecimen Collection(procedure)
- Enrollment
- 48 enrolled
- Eligibility
- 22 years · All sexes
- Timeline
- 2024 – 2028
Study locations (30)
- Children's Hospital of Alabama, Birmingham, Alabama, United States
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- Kaiser Permanente Downey Medical Center, Downey, California, United States
- Loma Linda University Medical Center, Loma Linda, California, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Valley Children's Hospital, Madera, California, United States
- UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
- Kaiser Permanente-Oakland, Oakland, California, United States
- Children's Hospital of Orange County, Orange, California, United States
- Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States
- UCSF Medical Center-Mission Bay, San Francisco, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver, Colorado, United States
- Connecticut Children's Medical Center, Hartford, Connecticut, United States
- Yale University, New Haven, Connecticut, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05828069 on ClinicalTrials.govOther trials for Langerhans cell histiocytosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07371182Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone LesionsWest China Second University Hospital
- RECRUITINGNANCT07431060Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell HistiocytosisWest China Second University Hospital
- ACTIVE NOT RECRUITINGPHASE2NCT07204041Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCHCancer Institute and Hospital, Chinese Academy of Medical Sciences
- RECRUITINGPHASE2NCT07022834Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in ChildrenWest China Second University Hospital
- RECRUITINGPHASE2NCT07187193Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCHCancer Institute and Hospital, Chinese Academy of Medical Sciences
- ENROLLING BY INVITATIONPHASE1NCT06902792Adebrelimab Combined With Trametinib in the Treatment of Refractory Recurrent Langerhans Cell Histiocytosis in Children and AdolescentsSecond Affiliated Hospital of Wenzhou Medical University
- RECRUITINGPHASE2NCT06582745Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, TrametinibCook Children's Health Care System
- RECRUITINGNCT06197204Biomarkers for Diagnostic, Prognostic and of Response to Treatment in Adult Langerhans Cell HistiocytosisAssistance Publique - Hôpitaux de Paris